Company Description
BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology.
The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.
Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer’s disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia.
In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia.
BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
| Country | United States |
| Founded | 2017 |
| IPO Date | Mar 8, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 74 |
| CEO | Vimal Mehta |
Contact Details
Address: 555 Long Wharf Drive, 12th Floor New Haven, Connecticut 06511 United States | |
| Phone | 475 238 6837 |
| Website | bioxceltherapeutics.com |
Stock Details
| Ticker Symbol | BTAI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001720893 |
| CUSIP Number | 09075P105 |
| ISIN Number | US09075P1057 |
| Employer ID | 82-1386754 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vimal D. Mehta Ph.D. | Founder, Chief Executive Officer, President, and Director |
| Richard I. Steinhart MBA | Senior Vice President and Chief Financial Officer |
| Dr. Frank D. Yocca Ph.D. | Senior Vice President and Chief Scientific Officer |
| Dr. Vincent J. O'Neill B.Sc., M.D., M.R.C.P. | Executive Vice President and Chief of Product Development and Medical Officer |
| Dr. Chetan D. Lathia Ph.D. | Senior Vice President and Head of Translational Medicine, Clinical Pharmacology and Regulatory Affairs |
| Dr. Robert Risinger M.D. | Chief Medical Officer - Neuroscience |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 18, 2024 | SCHEDULE 13G | Filing |
| Dec 18, 2024 | SCHEDULE 13G | Filing |
| Dec 18, 2024 | PRE 14A | Other preliminary proxy statements |
| Dec 16, 2024 | 144 | Filing |
| Dec 16, 2024 | 144 | Filing |
| Dec 16, 2024 | 144/A | Filing |
| Dec 16, 2024 | 144 | Filing |
| Dec 16, 2024 | 144 | Filing |
| Dec 16, 2024 | 144 | Filing |
| Nov 25, 2024 | 8-K | Current Report |